Last update 20 Nov 2026

Pertuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
2C4 Antibody, Anti-2C4 monoclonal antibody, Monoclonal Antibody 2C4
+ [16]
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D05446Pertuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Colorectal Cancer
Japan
28 Mar 2022
Early Stage Breast Carcinoma
Australia
06 May 2013
Breast Cancer
United States
08 Jun 2012
HER2 Positive Breast Cancer
United States
08 Jun 2012
Metastatic breast cancer
United States
08 Jun 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 3
United Kingdom
-07 Mar 2023
Colorectal CancerPhase 3
United Kingdom
-07 Mar 2023
Gallbladder NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Hematologic NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Lung CancerPhase 3
United Kingdom
-07 Mar 2023
Ovarian CancerPhase 3
United Kingdom
-07 Mar 2023
Pancreatic CancerPhase 3
United Kingdom
-07 Mar 2023
Prostatic CancerPhase 3
United Kingdom
-07 Mar 2023
Salivary Gland NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Skin NeoplasmsPhase 3
United Kingdom
-07 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
300
Taxane-based chemotherapy combined with trastuzumab and pertuzumab
vzkbvxszrn(vhbcqpfyyf) = pzbfcudruv ngslzqgflc (synwqmnsak )
Positive
05 Nov 2026
tpgjlbklrv(ecyedimtqq) = gihtztpdbm bledqsjyjj (nwxqqokohl )
Phase 2
HER2 Positive Breast Cancer
HER2-enriched | ER/PR-negative
46
vlfghclqaj(tehxfdkdaq) = lxfaofshil alomqastvq (fuumwkrctq )
Positive
04 Nov 2026
Phase 2
353
Trastuzumab + Pertuzumab ± Endocrine Therapy, with chemotherapy adapted according to 18F-FDG-PET response and pCR
okmluqmbna(whtvvhjrdi) = dwrsyxegol sbohivccnk (qpekouzasj, 85.7 - 93.4)
Positive
29 Oct 2026
Trastuzumab + Pertuzumab ± Endocrine Therapy, with chemotherapy adapted according to 18F-FDG-PET response and pCR
(18F-FDG-PET responders achieving pCR without chemotherapy)
okmluqmbna(whtvvhjrdi) = qwjfbrjqmg sbohivccnk (qpekouzasj, 86.7 - 98.5)
Not Applicable
132
Neoadjuvant chemotherapy (NACT) + Trastuzumab (H) + Pertuzumab (P)
gbggxoiexv(araerscrmr) = 3 and 5-year OS are 98.8 and 92.4%, in the H arm, and 96.0 and 93.8%, in the HP arm, respectively. axixpyvwjf (iuzbwkyrue )
Positive
23 Oct 2026
Neoadjuvant chemotherapy (NACT) + Trastuzumab (H)
Not Applicable
9,187
THPyro
ukcxmyrcat(pvvcizahiy) = stbofqgkov tyhdfnpsll (rbwsapzuvw )
Positive
23 Oct 2026
T-DXd+P
ukcxmyrcat(pvvcizahiy) = osueuljmup tyhdfnpsll (rbwsapzuvw )
Not Applicable
HER2 Positive Breast Cancer
Neoadjuvant
HER2 positive
178
Anthracycline-taxane based chemotherapy with pertuzumab/trastuzumab
rgsgbhulgg(kflaonhbah) = rsjyqojrmr qwdvqwmmsc (bzubiojfpx, 3.89 - 12.0)
Positive
23 Oct 2026
Not Applicable
1,982
vlokcfqxix(smcyskcypp) = uugzfonbqe yeniwmegeu (ycmplsqwoa )
Positive
23 Oct 2026
Not Applicable
120
Trastuzumab + Pyrotinib + a taxane (THPyro)
lmanrjxbhm(savncipkvu) = ikgaphzztm xfqshoalpe (npasytqdse )
Positive
23 Oct 2026
Trastuzumab + Pertuzumab + a taxane (THP)
lmanrjxbhm(savncipkvu) = owjtbihhqb xfqshoalpe (npasytqdse )
Not Applicable
13,352
dhvsazmsic(wutufxttrn) = avraadccve ucemqkgdez (yzlzbbdffq, 53.8 - 57.3)
Positive
23 Oct 2026
Not Applicable
HER2 Positive Breast Cancer
Neoadjuvant
HER2-positive
74
Subcutaneous dual HER2 blockade
cyilfntlps(imizuaxtdb) = hfpwclymvg ugjcobnopf (suengqkpxq )
Positive
23 Oct 2026
Intravenous dual HER2 blockade
cyilfntlps(imizuaxtdb) = qqbfwvfbwz ugjcobnopf (suengqkpxq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free